Reports Search

The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. 

This was one of the key messages at the close of the fourth meeting of the WHO Working Group on Amendments to the International Health Regulations, which concluded today after a week of discussions. 

Although most negotiations took place behind closed doors, the meeting report that was discussed briefly in a public session on Friday provided a snippet of the talks so far and the envisioned way forward.  

In the politically charged discussions that current global health negotiations have become, diplomats have to walk a tightrope between delivering on political goals and bringing in concrete reforms to beef up preparedness, prevention and respond to health emergencies. The relative low profile of the discussions surrounding the amendments to the IHR (2005) is in contrast to the optics generated by the negotiations for a Pandemic Accord. This could be partly by design, and partly by the very nature of these discussions that are technical but undoubtedly also political. During the sidelines of the WG-IHR4, Geneva Health Files, spoke with Abdullah Asiri and Ashley Bloomfield, Co-Chairs of the WG-IHR talk about how they see these negotiations progressing. Countries have often described this track fo global helathnegotiations as being efficient and streamlined.

The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. 

This was one of the key messages at the close of the fourth meeting of the WHO Working Group on Amendments to the International Health Regulations, which concluded today after a week of discussions. 

… According to global health charity Medicins Sans Frontieres (MSF), J&J currently prices the drug at USD1.50/day for an adult treatment (USD272/six months). But with scale-up and unrestricted generic competition, it says the price of bedaquiline could get closer to USD0.50 per day. … But even if the deal does bring the price down to that level, some of the countries which would benefit from purchasing the drug at a lower price will not be able to as they have been excluded from it. Nine countries in the Eastern European and Central Asian region, which have some of the highest TB burdens in the world, are not covered by the deal because of an exclusive supply agreement J&J has with a Russian pharma firm. … The exclusion has infuriated senior health officials in some of the excluded countries. In a rare instance of its kind, the national tuberculosis (TB) programme (NTP) of Belarus sent an open letter to J&J demanding urgent action to improve equitable access to bedaquiline in Belarus, and all other countries with a high burden of TB.

The fourth meeting of the Working Group on Amendments to the International Health Regulations (WGIHR4) is to discuss various developed country amendment proposals focusing on accelerated information sharing and compliance. These proposals are from the USA, the European Union (EU), Switzerland and New Zealand. WGIHR4 will take place at the WHO Headquarters in Geneva on 24-28 July in a hybrid mode. … The third meeting of WGIHR had focussed on amendment proposals on Article 13 (public health response), new article 13 A (equitable access to health products, technologies and know-how), 43 (additional health measures), 44 (collaboration and cooperation), new article 44A (financing mechanism), New Article 53A (implementation and compliance). This week the majority of the amendment proposals under consideration are from developed countries. Many of these aim at enhancing the obligations on information sharing and compliance that on the surface seem reasonable but can be negative for developing countries.

High cost has prevented some cancer drugs from being included in the World Health Organization’s (WHO) updated Essential Medicines List (EML) and Essential Medicines for List Children (EMLc) released on Wednesday.

These include “patented, highly-priced” treatments for lung and breast cancer.

“With the cancer medicines, we are facing now an issue where we have a very high burden of disease and very expensive, highly-priced medicines,” said Dr Benedikt Huttner, secretary of the expert committee that advises the WHO on the EML.

“For some of the medicines [cost] was one of the factors leading the expert committee not to recommend them currently,” Huttner told a WHO global press conference.

The final reading of the Political Declaration for the United Nations High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR) is scheduled for Tuesday in New York – and while the revised text has a few more practical clauses than the bland zero-draft, it remains more aspirational than actionable. The revised version, which has been shared with Health Policy Watch, puts “equitable, people-centered and community-based” primary health care at the centre of countries’ pandemic mitigation. … In terms of equity, the declaration commits to strengthening “research and development capacity in developing countries” funded by “greater official development assistance”, surge financing and other “innovative financing”.

Before COVID-19 came along, the two most lethal infectious diseases were HIV and tuberculosis (TB). Even though HIV still lingers, with 1.5 million people contracting the infection every year, epidemiologists point to the availability of many HIV prevention options as a primary reason for the decreasing caseload.

According to the World Health Organization (WHO), over the past two decades, new HIV infections decreased by 49%, HIV-related deaths decreased by 61% and an estimated 18.6 million lives were saved because of new treatments that minimise the infection and prevent its spread.

The Inter-Organization Programme for the Sound Management of Chemicals (IOMC) is submitting report on recent progress on Emerging Policy issues and Other Issues of Concern, identified under SAICM. These issues are part of the 19 Issues considered in the Assessment report on issues of concern, and are for which UNEP was asked to seek views on priorities for further work and on potential further international action, by UNEA resolution 5/7.

That definitive conclusion has energized a major HIV/AIDS conference this week